Efficacy of treatment, including its immediate and longterm outcomes, in 109 patients with atypical respiratory sarcoidosis were analysed. The treatment regimens were as follows: corticosteroid hormones supplemented by delagil and vitamin E, intermittent corticosteroid therapy, administration of long-acting++ corticosteroid hormones and treatment with presocyl, delagil and vitamin E. Due to the given treatment, a favourable clinical effect was achieved in 74.3% of the cases with the process remaining stable in 2.8% and recurrent development of the disease in 22.9%. Persistent favourable outcomes in a distant future were registered in 82.9%, stable process--in 3.9%, and progression with aggravation and relapses--in 13.2% of the patients.